Efficacy and safety of ODM-101 compared to a standard combination(Stalevo®) in patients with Pakinson's disease.

Conditions: Parkinson's disease
MedDRA version: 14.0Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Registration Number: EUCTR2010-022200-46-LV

Lead Sponsor: Orion Corporation

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

• Written informed consent (IC) obtained.
• Male or female patients with idiopathic PD according to the United
Kingdom brain bank criteria with end-of-dose -motor fluctuations.
• Hoehn and Yahr stage 2-4 performed during the ON state.
• An average of ? 3.0 hours of OFF-time, with a minimum of 0.5 hours of
OFF-time on each day (using PD home diary [hereafter diary] data
before baseline measurements) on 3 consecutive days before the
decision of entry.
• Treatment with 4-8 daily doses of levodopa/DDCI with entacapone
(either levodopa/DDCI combined with Comtess®/Comtan® or as
Stalevo®) or without entacapone with a total daily levodopa dose in the
range of 400-1200 mg. One evening dose of controlled-release
formulation of levodopa/DDCI is allowed providing that it is included in the total of 4-8 daily doses of levodopa/DDCI mentioned above. Use of
soluble levodopa formulations, such as Madopar LT or Quick, up to a
maximum of 4 doses per week is allowed; however, its use should be
avoided on days during which PD status (diary) is recorded. The
levodopa dose from these soluble levodopa formulations is not included
in the range of total daily dose of levodopa indicated above.
• Unchanged levodopa/DDCI with or without entacapone and other
antiparkinsonian medication (dopamine agonists, monoamine oxidase
[MAO] B inhibitor, amantadine and/or anticholinergics with doses
recommended by the manufacturer), if any, for at least 4 weeks prior to
the screening visit.
• Age of 30 years or above.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 60

Exclusion Criteria

• Secondary or atypical parkinsonism.
• Current use of tolcapone (within 6 weeks prior to the first treatment
period).
• Previous tolerability problems with entacapone or tolcapone.
• Concomitant treatment with apomorphine, MAO-A inhibitors or nonselective
MAO inhibitors.
• Concomitant treatment with drugs having antidopaminergic action
including alpha-methyldopa, reserpine and antipsychotic drugs (also
dopamine D2 receptor blocking antiemetics except domperidone). As an
exception to the prohibition of use of antipsychotic drugs, 1 evening
dose of an atypical antipsychotic is allowed.
• Severe dyskinesias as judged by the investigator; however, mild to
moderate dyskinesia not significantly affecting patient's activities of
daily living is allowed.
• Currently active hallucinations.
• Severe orthostatic hypotension as judged by the investigator.
• Current dementia (Mini-Mental State Examination [MMSE] score < 24).
• Problematic impulse control disorders (ICD) such as pathological
gambling, hypersexuality or compulsive shopping within 6 months prior
to the screening visit.
• History of neuroleptic malignant syndrome (NMS) and/or nontraumatic
rhabdomyolysis.
• Past or current treatment with deep brain stimulation (DBS) or other
surgical treatment for PD.
• Narrow-angle glaucoma or pheochromocytoma.
• Any active malignant cancer.
• Patients with pre-planned elective surgery.
• Failure to demonstrate acceptable/appropriate use of the diary,
despite adequate training, during the screening visit or other separate
training sessions during the screening period.